An observational, prospective, open-label to assess effectiveness, safety and tolerability of once-yearly treatment with zoledronic acid in osteoporotic patients in a real-world setting (AZURE).
2020-07-04
عنوان الدراسة
An observational, prospective, open-label to assess effectiveness, safety and tolerability of once-yearly treatment with zoledronic acid in osteoporotic patients in a real-world setting (AZURE).
داعم الدراسة
Novartis
دواء الدراسة
Zoledronic acid
رقم بروتوكول الدراسة
CZOL446H-MAX-SA-01
حالة الدراسة
Completed
موقع الدراسة
King Fahad University Hospital (Al-Khobar), King Khalid University Hospital (Riyadh)
مرحلة الدراسة
4
评论与建议
如对政府服务有任何咨询或意见,请填写所需信息。